Real-world incidence of G3-G4 adverse events with enfortumab vedotin in patients with advanced urothelial carcinoma (ARON-2EV study)

Résumé fourni par la source

Abstract Enfortumab vedotin (EV) is an antibody–drug conjugate targeting Nectin-4 and is approved for patients with advanced urothelial carcinoma (UC) who have progressed after platinum-based chemotherapy and immune checkpoint inhibitors. While clinical trials have demonstrated manageable safety profiles, real-world toxicity data remain limited. We conducted a multi-center retrospective study of consecutive patients with locally advanced or metastatic UC treated with EV between January 2022 and April 2025. Demographic, clinical, and treatment-related data were extracted from electronic medical records. Primary endpoints included incidence of G3-G4 AEs, dose reductions, and discontinuations. A total of 770 patients were included; 195 patients (25%) reported G3-G4 AEs. The most common G3-G4 AEs were dermatologic (10%), neuropathy (9%) and diarrhea (7%). Seventy-four patients (10%) discontinued EV due to G3-G4 AEs. Both the median OS (21.3 months vs 16.1 months, p = 0.010) and PFS (8.2 months vs 6.8 months, p = 0.012) were significantly longer in patients who started EV therapy at standard dose versus at reduced dose. In conclusion, this real-world cohort showed that EV demonstrated a toxicity profile broadly consistent with clinical trial data, though rates of dose modification were substantial. Enhanced monitoring and early toxicity management may optimize treatment continuity in advanced UC patients.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.